We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Rates of patency and device-related thrombus were ...
Please provide your email address to receive an email when new articles are posted on . In a head-to-head trial of the Amplatzer Amulet and Watchman FLX left atrial appendage closure devices, the ...
European regulators have approved an expanded indication for the Boston Scientific Corporation BSX WATCHMAN® Left Atrial Appendage (LAA) Closure Device. The new indication offers patients with atrial ...
New stroke risk reduction therapy with thromboresistant coating is designed to advance procedural performance and safety MARLBOROUGH, Mass., Sept. 6, 2023 /PRNewswire/ -- Boston Scientific Corporation ...
In the showdown between left atrial appendage (LAA) closure devices, the Amplatzer Amulet outperformed Watchman for peridevice leaks (PDL) in one trial longer term but not in another. At 12 months of ...
The global left atrial appendage closure (LAAC) devices market is projected to register a robust growth from 2025 to 2033.
Data also demonstrates that the stroke risk reduction device is as effective as oral anticoagulants for patients with atrial fibrillation following a cardiac ablation The trial met the primary safety ...
On the basis of outcomes, there was no clear winner from a trial that directly compared two modern devices used in patients undergoing percutaneous left atrial appendage (LAA) closure. But the devices ...
Boston Scientific Corp. and Abbott Laboratories continue to parry over clinical trials comparing the latter’s Amplatzer Amulet with Boston Scientific’s Watchman in sealing the heart’s left atrial ...
SWISS-APERO is the first randomized clinical trial comparing Amulet with the new generation Watchman FLX device in terms of residual left atrial appendage (LAA) patency after percutaneous LAA closure ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results